Michiko Yamato YOU? Author Swipe

Last 10y

End-to-end Anastomosis With ECHELON ENDOPATH™ Staple Line Reinforcement for Right-sided Colon Cancer: Safety and Feasibility Open

Yasuhiro Ishiyama, Yasumitsu Hirano, Megumi Sasaki, Sohei Akuta, Masatoshi Yoshizawa , et al. · 2025

SLR represents a safe and effective adjunctive technique for FEEA in right-sided colon cancer surgery. Further validation through larger prospective studies is warranted to confirm these preliminary results.

Supplementary Data from DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models Open

Michiko Yamato, Jun Hasegawa, Takanori Maejima, Chiharu Hattori, Kazuyoshi Kumagai , et al. · 2023

Supplementary Data from DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models

Supplementary Data from DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models Open

Michiko Yamato, Jun Hasegawa, Takanori Maejima, Chiharu Hattori, Kazuyoshi Kumagai , et al. · 2023

Supplementary Data from DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models

Data from DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models Open

Michiko Yamato, Jun Hasegawa, Takanori Maejima, Chiharu Hattori, Kazuyoshi Kumagai , et al. · 2023

B7-H3 is overexpressed in various solid tumors and has been considered as an attractive target for cancer therapy. Here, we report the development of DS-7300a, a novel B7-H3–targeting antibody–drug conjugate with a potent DNA topoisomerase…

Data from DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models Open

Michiko Yamato, Jun Hasegawa, Takanori Maejima, Chiharu Hattori, Kazuyoshi Kumagai , et al. · 2023

B7-H3 is overexpressed in various solid tumors and has been considered as an attractive target for cancer therapy. Here, we report the development of DS-7300a, a novel B7-H3–targeting antibody–drug conjugate with a potent DNA topoisomerase…

Figure S1 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity Open

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato , et al. · 2023

The B7-H3 staining pattern for diagnosis

Figure S2 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity Open

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato , et al. · 2023

Effect of using a combination of targeting B7-H3 and PD-L1 on body weight in the murine tumor model

Table S1 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity Open

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato , et al. · 2023

Characteristics of patients treated with anti-PD-1 antibody

Table S1 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity Open

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato , et al. · 2023

Characteristics of patients treated with anti-PD-1 antibody

Figure S2 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity Open

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato , et al. · 2023

Effect of using a combination of targeting B7-H3 and PD-L1 on body weight in the murine tumor model

Data from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity Open

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato , et al. · 2023

Purpose: Anti-programmed-death-1 (PD-1) immunotherapy improves survival in non–small cell lung cancer (NSCLC), but some cases are refractory to treatment, thereby requiring alternative strategies. B7-H3, an immune-checkpoint molecul…

Table S3 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity Open

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato , et al. · 2023

Cox proportional hazard model for PFS

Table S2 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity Open

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato , et al. · 2023

Effect of PD-L1 and B7-H3 expression on response rate

Data from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity Open

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato , et al. · 2023

Purpose: Anti-programmed-death-1 (PD-1) immunotherapy improves survival in non–small cell lung cancer (NSCLC), but some cases are refractory to treatment, thereby requiring alternative strategies. B7-H3, an immune-checkpoint molecul…

Table S3 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity Open

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato , et al. · 2023

Cox proportional hazard model for PFS

Figure S1 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity Open

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato , et al. · 2023

The B7-H3 staining pattern for diagnosis

Table S2 from B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity Open

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato , et al. · 2023

Effect of PD-L1 and B7-H3 expression on response rate

DS-7300a, a novel B7-H3-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, exhibits potent anti-tumor effects in nonclinical models Open

Michiko Yamato, Jun Hasegawa, Chiharu Hattori, Takanori Maejima, Tomoko Shibutani , et al. · 2020

Novel anti-EPHA2 antibody, DS-8895a for cancer treatment Open

Jun Hasegawa, Mayumi Sue, Michiko Yamato, Junya Ichikawa, Saori Ishida , et al. · 2016

Overexpression of EPHA2 has been observed in multiple cancers and reported to be associated with poor prognosis. Here, we produced an afucosylated humanized anti-EPHA2 monoclonal antibody (mAb), DS-8895a for cancer treatment. The antibody …

Development of <span>DS</span>‐5573a: A novel afucosylated <span>mA</span>b directed at B7‐H3 with potent antitumor activity Open

Akiko Nagase‐Zembutsu, Kenji Hirotani, Michiko Yamato, Junko Yamaguchi, Takehiko Takata , et al. · 2016

B7‐H3 is highly overexpressed in a variety of human clinical tumors, and its expression is significantly associated with poor outcomes. In our study, we aimed to develop new antitumor mA bs by employing cancer cell immunization, and succee…

Fetching topic information...